Acucela Founder to Speak at BioVentures Conference.Dr. Kubota This article is about Kubota Corporation. For other uses of "Kubota", see Kubota (Disambiguation). Kubota Corporation (株式会社クボタ to discuss blinding eye disease therapy as one of featured speakers BOTHELL, Wash. -- Acucela founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. Ryo Kubota will discuss the company's work toward developing a treatment for age-related blindness at a conference that attracts a mix of biotechnical, pharmaceutical and venture capital executives, the company announced today. Acucela plans to begin Phase II trials this summer on ACU-4429, an innovative oral therapy to cure conditions that most commonly cause age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ). Dr. Kubota will discuss the company's clinical findings related to the drug's development Thursday at the 11th Annual C21 BioVentures conference in Napa, Calif. "Acucela is developing a therapy that will potentially prevent blindness in tens of millions of people," Dr. Kubota said. "This less-invasive treatment would dramatically improve the quality of life for people around the world as they age." C21 BioVentures attracts senior biotechnology, pharmaceutical, and venture capital executives to hear presentations from representatives of the world's most innovative private companies. Acucela, based in Bothell, Wash., is developing ACU-4429 in partnership with Otsuka Pharmaceutical, Co., Ltd., a large Japanese company. AMD afflicts 30 million people worldwide and is the leading cause of blindness in the aging population. Dr. Kubota is scheduled to present on Thursday at 1:30 p.m. at the Meritage Resort. About Acucela Acucela Inc. is a clinical-stage biotechnology company focused on developing new drug therapies for blinding eye diseases such as age-related macular degeneration (AMD), Stargardt disease, diabetic retinopathy diabetic retinopathy n. Retinal changes occurring in long-term diabetes and characterized by punctate hemorrhages, microaneurysms, and sharply defined waxy exudates. and retinopathy of prematurity retinopathy of prematurity n. Abnormal replacement of the sensory retina by fibrous tissue and blood vessels, occurring mainly in premature infants who are placed in a high-oxygen environment. , as well as dry eye. Founded in 2002, Acucela works with proprietary disease-specific assays and technologies to identify and develop compounds that may safely and effectively treat retinal retinal /ret·i·nal/ (ret´i-n'l) 1. pertaining to the retina. 2. the aldehyde of retinol, derived from absorbed dietary carotenoids or esters of retinol and having vitamin A activity. diseases. For more information, please visit www.acucela.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion